Abu-Izza K, Tambrallo L, Lu D R
College of Pharmacy, University of Georgia, Athens 30602, USA.
J Pharm Sci. 1997 May;86(5):554-9. doi: 10.1021/js960461b.
The purpose of this study was to evaluate the in vivo performance of sustained-release zidovudine (AZT) microspheres after oral administration in Beagle dogs, and to establish an in vitro-in vivo correlation. Two AZT microsphere formulations as well as AZT powder were administered to four Beagle dogs. Plasma samples were analyzed by HPLC. The plasma concentration-time data was analyzed by both compartmental and noncompartmental pharmacokinetic analyses. Based on the calculated pharmacokinetic parameters, in vivo release profiles were simulated and compared with in vitro release profiles in three different release media. Significantly longer mean residence time (MRT) was observed after administration of the sustained-release microspheres compared with AZT powder. Significantly lower maximum (Cmax) concentration values and longer times to Cmax (tmax) values were also observed. Formulation I showed the longest MRT (4.4 h). AZT plasma concentration was maintained above the minimum effective concentration for approximately 10 h after administration of Formulation I. The relative bioavailability of the microsphere formulations with respect to AZT powder was not significantly different from 1. The in vitro release of the three formulations was slower in simulated gastric fluid compared with simulated intestinal fluid. The addition of enzymes and mucin to the release media significantly lowered the in vitro release rate of AZT from the microspheres formulations, but not from AZT powder. A good level of in vitro-in vivo correlation (Level A correlation) was achieved with a release medium that was composed of simulated gastric fluid with pepsin and mucin for 2 h followed by simulated intestinal fluid with pancreatin and mucin for 8 h. This in vitro model may be used to predict the in vivo release of AZT, in the further development of controlled-release AZT formulations.
本研究的目的是评估口服给药后齐多夫定(AZT)缓释微球在比格犬体内的性能,并建立体外-体内相关性。将两种AZT微球制剂以及AZT粉末给予四只比格犬。通过高效液相色谱法分析血浆样本。通过房室和非房室药代动力学分析对血浆浓度-时间数据进行分析。基于计算得到的药代动力学参数,模拟体内释放曲线并与三种不同释放介质中的体外释放曲线进行比较。与AZT粉末相比,给予缓释微球后观察到平均驻留时间(MRT)显著延长。还观察到最大(Cmax)浓度值显著降低,达到Cmax的时间(tmax)延长。制剂I显示出最长的MRT(4.4小时)。给予制剂I后,AZT血浆浓度在给药后约10小时内维持在最低有效浓度以上。微球制剂相对于AZT粉末的相对生物利用度与1无显著差异。与模拟肠液相比,三种制剂在模拟胃液中的体外释放较慢。向释放介质中添加酶和粘蛋白显著降低了AZT从微球制剂中的体外释放速率,但未降低从AZT粉末中的释放速率。使用由含有胃蛋白酶和粘蛋白的模拟胃液2小时,随后含有胰酶和粘蛋白的模拟肠液8小时组成的释放介质,实现了良好的体外-体内相关性(A级相关性)。在AZT控释制剂的进一步开发中,该体外模型可用于预测AZT的体内释放。